At the same time, the application of antiplatelet therapy in ALI patients can help reduce the levels of serum D-dimer, NT-pro BNP and platelets, promote the reduction of lung injury and the risk of ARDS. This evidence concerns the gene NPPB and acute respiratory distress syndrome.